Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 382

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 382
---
 page or by written request to the Company at Mosaic ImmunoEngineering, Inc., 9114 Adams
Avenue, #202, Huntington Beach, California 92646, Attention: Corporate Secretary.

Due to the Company’s size, its limited operations,
and limited cash on hand during the year ended December 31, 2024, the Board of Directors were not actively engaged in all aspects each
committee charter.

Director Independence

Under Nasdaq Marketplace Rule 5605(a)(2), a director
will not be considered an “independent director” if, such director at any time during the past three years was an employee
of the Company, or if a director (or a director’s family member) accepted compensation from the Company (other than compensation
for board or board committee service) in excess of $120,000 during any twelve month period within the three years preceding the determination
of independence. In addition, a director will not qualify as an “independent director” if, in the opinion of our Board of
Directors, that person has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities
of a director. Our Board has determined that Dr. Baffi and Dr. Garnick are “independent directors” within the meaning of Nasdaq
Marketplace Rule 5605(a)(2).

Certain Relationships

There are no family relationships between or among
the Board or executive officers. 

Annual Meeting Attendance

Our policy is to invite and encourage each member
of our Board to be present at any annual meetings of stockholders. During the year ended December 31, 2024, there was no annual meeting
of stockholders.

Director Compensation

We did not pay any compensation, make any equity awards
or non-equity awards to or pay any other compensation to any of our non-employee directors during the year ended December 31, 2024. In
addition, we reimburse all directors for travel and other necessary business expenses incurred in the performance of their services for
us.

Board Leadership Structure

In accordance with our Amended and Restated Bylaws
(“Bylaws”), our Chief Executive Officer serves as the Chairman of the Board. The Board determined that in the best interest
of the Company, the most effective leadership structure at this time is not to separate the roles of Chairman and Chief Executive Officer
pursuant to the Bylaws. A combined structure will provide the Company with a single leader who represents the Company to our stockholders